Stay updated on Nivolumab and Axitinib in RCC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Axitinib in RCC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for nivolumab plus axitinib in advanced renal cell carcinoma is displayed, including participant eligibility and locations, study design and outcomes, and a study protocol document. The record also identifies the study as active but no longer recruiting.
    Difference
    55%
    Check dated 2026-11-08T13:52:31.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:08:48.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T14:07:47.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:19:53.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the error page.
    Difference
    0.2%
    Check dated 2026-10-11T14:19:06.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The page now presents a 403 Forbidden error page, replacing the study record content. The site header and footer remain visible.
    Difference
    20%
    Check dated 2026-09-20T20:29:31.000Z thumbnail image

Stay in the know with updates to Nivolumab and Axitinib in RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Axitinib in RCC Clinical Trial page.